Core Viewpoint - Federal Pharmaceutical's innovative drug UBT251 has shown significant weight loss results in its Phase II clinical trial for overweight/obese patients in China, supporting its advancement to Phase III trials [2][5]. Group 1: Clinical Trial Results - UBT251 injection demonstrated a maximum average weight loss of -19.7% (-17.5 kg) after 24 weeks in the treatment group, compared to -2.0% (-1.6 kg) in the placebo group [2][5]. - Improvements in key secondary endpoints such as waist circumference, blood sugar, blood pressure, and blood lipids were significantly better in the UBT251 groups compared to the placebo [2][5]. Group 2: Safety and Tolerability - The overall safety and tolerability of UBT251 were good, with no withdrawals due to adverse events reported [2][5]. - Adverse events were similar to those of comparable drugs, primarily gastrointestinal reactions, with the majority being mild to moderate, and no unexpected safety issues were observed [2][5]. Group 3: Future Developments - The successful completion of the Phase II trial supports the initiation of the Phase III clinical study for UBT251 in overweight/obese patients in China [2][5].

华人置业(00127)预期2025年可能取得亏损减少75%至85%，但收入减少5%至15%，2024年其收入为3.37 亿港元，公司拥有人应占的综合亏损净额为21.08亿港元。 2月25日，港股集体高开，其中恒生指数涨0.58%报26745.2点，恒生科技指数涨0.86%报5316.09点，国 企指数涨0.68%报9069.19点，红筹指数涨0.41%报4464.07点；昨日港股三大指数集体走低，恒指再度失 守两万七大关、恒科指数跌超2%。 盘面上，大型科技股普遍走高，阿里巴巴涨1.22%，腾讯控股涨0.48%，京东集团涨1.03%，网易涨 1.51%，美团涨1.23%，快手涨0.38%；中资券商股活跃，中信建投证券涨超1%；有色金属板块高开， 中国宏桥涨超3%；半导体部分上涨，华虹半导体涨超1%。AI应用股走强，KEEP涨3.94%、出门问问涨 3.17%、范式智能涨2.82%、海致科技集团涨2.38%。 公司业绩有喜有忧 多家公司公布业绩情况 猫眼娱乐(01896.HK)表现亮眼，2025财年收入预计达46亿 - 47亿元，同比增长约12.7%至15.1%；净利润 5.4亿 - 5.9亿元，同比增长约19 ...

Core Viewpoint - Federal Pharmaceutical's innovative drug UBT251 has shown significant weight loss results in overweight/obese patients during its Phase II clinical trial in China, supporting its advancement to Phase III trials [1] Group 1: Clinical Trial Results - UBT251 injection demonstrated a maximum average weight loss of -19.7% (-17.5 kg) after 24 weeks in the treatment group, compared to -2.0% (-1.6 kg) in the placebo group [1] - Key secondary endpoints, including waist circumference, blood sugar, blood pressure, and blood lipids, showed significant improvement in the UBT251 groups compared to the placebo [1] - The overall safety and tolerability of UBT251 were good, with no withdrawals due to adverse events, and adverse events were similar to those of comparable drugs, primarily gastrointestinal reactions [1] Group 2: Future Development - The successful results of the Phase II clinical trial support the initiation of Phase III clinical trials for UBT251 in overweight/obese patients in China [1]

Group 1 - AMD and Meta have reached a strategic partnership agreement for the procurement of AI chips worth up to $60 billion over the next five years, marking a significant shift in the AI chip market dynamics [1] - This agreement signifies Meta's transition from being a hardware buyer to a strategic partner in the supply chain, providing AMD with its largest single order in history [1] - AMD's AI chips, such as the MI300 series, rely heavily on advanced packaging technologies like CoWoS, indicating a substantial demand for high-quality packaging capabilities [1] Group 2 - ASMPT, a leading semiconductor packaging equipment supplier, is expected to benefit directly from the expansion of AMD and the overall industry due to its key equipment for advanced packaging [2] - The major demand for advanced packaging capacity is driven by Meta's large order, with TSMC being the primary provider of CoWoS capacity [1][2] Group 3 - The Nasdaq China Golden Dragon Index rose by 1.37%, reflecting a positive trend in popular Chinese concept stocks, including AMD, which saw an increase of over 8% [3] - Major technology stocks, including Intel and Tesla, also experienced gains, contributing to the overall positive market sentiment [3] Group 4 - Panasonic has decided to transfer its TV sales business in North America and Europe to Skyworth, focusing instead on the Japanese market and high-end model production to reduce costs [4] - This strategic adjustment aligns with Panasonic's goal to optimize its operational model based on regional market conditions [4] Group 5 - Federal Pharmaceutical's UBT251 injection has completed Phase II clinical research in overweight/obese patients in China, indicating progress in its innovative drug development [5] - Haizhi Technology Group has entered a strategic cooperation framework agreement with Zhizhu Technology to collaborate in model training and application scenarios [6][7] Group 6 - Sanofi's partnership with Pfizer has led to significant revenue recognition, with a reported net profit of 2.939 billion yuan for 2025, reflecting a 317.09% year-on-year increase [8] - The company achieved a revenue of 4.199 billion yuan for the same period, marking a 251.81% increase [8] Group 7 - Harbin Electric has forecasted a net profit of 2.65 billion yuan for 2025, representing a year-on-year growth of approximately 57.2%, driven by increased revenue and improved product profitability [13] - The company is expected to benefit from the high demand for reliable power systems in the U.S. due to ongoing electricity shortages [13]

诺和诺德授权的实验性减肥药物UBT251在中国的二期临床试验中取得了显著的减重效果，为该公司在竞争激烈的减肥药市场中寻找新的增长引擎 提供了有力支撑。 据诺和诺德的中国合作伙伴联邦制药报告，中国肥胖和超重患者在服用该药物24周后，体重降幅最高达到了19.7%，而相比之下，服用安慰剂的 患者平均减重仅为2%。 诺和诺德研发负责人 Martin Holst Lange 在一份声明中表示，公司对此次中国试验的数据感到"非常受鼓舞"。基于这一积极的中期结果，联邦制药 将在中国启动三期临床试验，而诺和诺德则计划在2027年公布其正在进行的全球早期试验的顶线数据。 尽管新药数据亮眼，但诺和诺德近期在资本市场的表现依然承压。周二，受其下一代减肥药Cagrisema的负面消息及多位分析师下调评级的影响， 诺和诺德股价盘中跌幅一度达到4.4%。在过去一年中，该公司股价累计下跌已超过60%。 三重激动剂展现更高潜力 此次公布的临床数据揭示了多靶点药物在减重领域的潜力。共有205名患者参与了这项二期试验，他们被随机分配接受2mg、4mg、6mg剂量的药 物或安慰剂。目前的试验结果是基于所有患者按计划坚持服药的预估得出的，目前尚未提 ...

Core Viewpoint - Federal Pharmaceutical's UBT251 injection has successfully completed Phase II clinical trials for overweight/obese patients in China, demonstrating significant weight loss and safety [1][2] Group 1: Clinical Study Details - The Phase II clinical study involved 205 participants with a baseline average weight of 92.2 kg and a BMI of 33.1 kg/m2 [1] - Participants were randomly assigned to receive UBT251 at doses of 2mg, 4mg, or 6mg, or a placebo, with weekly subcutaneous injections for 24 weeks [1] Group 2: Study Results - After 24 weeks, the UBT251 treatment groups achieved an average weight reduction of up to -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2] - Improvements in key secondary endpoints such as waist circumference, blood sugar, blood pressure, and blood lipids were significantly better in the UBT251 groups compared to the placebo [2] Group 3: Safety and Next Steps - UBT251 demonstrated good overall safety and tolerability, with no withdrawals due to adverse events, which were primarily mild to moderate gastrointestinal reactions [2] - The successful Phase II results support the initiation of Phase III clinical trials for overweight/obese patients in China [2]

Core Viewpoint - The clinical study of UBT251 injection, developed by the company's subsidiary, has successfully completed Phase II trials in overweight/obese patients in China, demonstrating significant weight loss and safety [1][2]. Group 1: Clinical Study Design and Results - The Phase II clinical study involved 205 participants with a baseline average weight of 92.2 kg and a BMI of 33.1 kg/m², using a randomized, double-blind, placebo-controlled design [1]. - Participants were assigned to receive either UBT251 injection at doses of 2mg, 4mg, or 6mg, or a placebo, with weekly subcutaneous injections for 24 weeks [1]. - The primary endpoint was the percentage change in weight from baseline after 24 weeks of treatment [1]. Group 2: Efficacy and Safety Outcomes - Results showed that the UBT251 treatment groups achieved a maximum average weight reduction of -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2]. - Key secondary endpoints, including waist circumference, blood sugar, blood pressure, and blood lipids, showed significant improvement in the UBT251 groups compared to placebo [2]. - The overall safety and tolerability of UBT251 were good, with no withdrawals due to adverse events, which were primarily gastrointestinal and mostly mild to moderate in severity [2].

Core Viewpoint - The company has successfully completed Phase II clinical trials for its innovative drug UBT251 injection in overweight/obese patients in China, demonstrating significant weight loss and safety profile [1][2]. Group 1: Clinical Trial Details - The Phase II clinical study involved 205 participants with obesity (BMI ≥ 28.0 kg/m²) or overweight patients with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²) [1]. - Participants were randomly assigned in a 1:1:1:1 ratio to receive UBT251 injection at doses of 2 mg, 4 mg, or 6 mg, or a placebo, administered once weekly for 24 weeks [1]. - The primary endpoint was the percentage change in weight from baseline after 24 weeks of treatment [1]. Group 2: Results and Efficacy - After 24 weeks, the UBT251 treatment groups achieved a maximum average weight reduction of -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2]. - Significant improvements were also observed in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids, all showing better results than the placebo [2]. Group 3: Safety and Next Steps - The overall safety and tolerability of UBT251 were good, with no participants dropping out due to adverse events, which were similar to those of comparable drugs and mostly mild to moderate gastrointestinal reactions [2]. - The successful Phase II results support the progression to Phase III clinical trials for UBT251 in overweight/obese patients in China [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本集團產品 UBT251 注射液臨床研究進展 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會（「董事會」）欣然公佈，本公司全資附屬公司聯邦生物科技（珠海橫琴） 有限公司（「聯邦生物科技」）自主研發的 1 類創新藥 UBT251 注射液已完成在中國超 重/肥胖患者中的 II 期臨床研究（「本研究」）。 UBT251 是一款長效 GLP-1（胰高血糖素樣肽-1）/GIP（葡萄糖依賴性促胰島素多肽）/GCG （胰高血糖素）三靶點受體激動劑。截至目前，已獲准在中國及/或美國開展成人 2 型糖 尿病、超重/肥胖、慢性腎臟病、代謝相關脂肪性肝炎多個適應症的臨床試驗。本公司是 中國首家、全球第二家以化學合成多肽法製備的長效 GLP-1R/GIPR/GCGR 三靶點激動 劑獲批臨床的企業。 於二零二五年三月，聯邦生物科技及本公司與諾和諾德股份有限公司已訂立關於 UBT251 的獨家許可協議。 ...

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]